Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GLA | P06280 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281890 | 0.89 | KMT2A (0.58) | KMT2AALDH1A1GLAHPGDKDM4E | |
| SCHEMBL27953547 | 0.86 | KMT2A (0.51) | KMT2AALDH1A1GLAHPGDKDM4E | |
| SCHEMBL29631756 | 0.85 | KMT2A (0.58) | KMT2AALDH1A1GLAHPGDKDM4E | |
| SCHEMBL23421423 | 0.85 | KMT2A (0.58) | KMT2AALDH1A1GLAHPGDKDM4E | |
| SCHEMBL9848724 | 0.84 | KMT2A (0.53) | KMT2AALDH1A1GLAHPGDKDM4E | |
| SCHEMBL30862644 | 0.84 | KMT2A (0.53) | KMT2AALDH1A1GLAHPGDKDM4E | |
| SCHEMBL28100860 | 0.83 | ALDH1A1 (0.49) | KMT2AALDH1A1GLAHPGDKDM4E | |
| Ammonia Solution, Strong SCHEMBL27611220 | 0.82 | KMT2A (0.51) | KMT2AALDH1A1GLAHPGDKDM4E | |
| Acridine SCHEMBL28339251 | 0.82 | ALDH1A1 (0.52) | KMT2AALDH1A1GLAHPGDKDM4E | |
| Water SCHEMBL28249523 | 0.82 | KMT2A (0.51) | KMT2AALDH1A1GLAHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-2033952-B1 | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity | SHIONOGI & CO (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1541558-A1 | HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1375486-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-0755457-A4 | NOVEL ARYL-N-ALKYLACRIDANTHIOCARBOXYLATE DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION | LUMIGEN INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0755457-A1 | NOVEL ARYL-N-ALKYLACRIDANTHIOCARBOXYLATE DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION | LUMIGEN, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028495-A1 | NOVEL ARYL-N-ALKYLACRIDANTHIOCARBOXYLATE DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION | LUMIGEN, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| US-3978079-A | DIPHTHALIMIDO, DISUCCINIMIDO AND DIMALEIMIDO OXALATES | AMERICAN CYANAMID COMPANY (US) | 1976-08-31 | — | — | US | disclosed |
| US-3970660-A | BIS(1,2-DIHYDRO-2-OXO-1-PYRIDYL) GLYOXAL | AMERICAN CYANAMID COMPANY (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | KMT2A 516/4885ALDH1A1 658/4885GLA 1840/4885 |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | DUT, PNP, INMT | KMT2A 186/4885ALDH1A1 1123/4885GLA 1277/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | KMT2A 667/4885ALDH1A1 424/4885GLA 1815/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | KMT2A 667/4885ALDH1A1 424/4885GLA 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.